Vanguard Global Advisers
IBRX icon

Vanguard Global Advisers’s ImmunityBio IBRX Stock Holding History

Vanguard Global Advisers’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.38M Buy
157,793
+9,073
+6% +$68.7K ﹤0.01% 1535
2026
Q1 		$1.14M Buy
+148,720
New +$1.02M ﹤0.01% 1571

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Global Advisers's IBRX Position: Q2 2026 in Review

Vanguard Global Advisers increased its ImmunityBio (IBRX) stake by 6.1% in Q2 2026, buying an estimated $68.7K and bringing the position to 157,793 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1535.

Vanguard Global Advisers first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 400 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Vanguard Global Advisers held 157,793 shares of ImmunityBio worth $1.38M as of Q2 2026.
  • Vanguard Global Advisers bought 9,073 ImmunityBio shares in Q2 2026, an estimated $68.7K.
  • ImmunityBio made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1535 holding.
  • Vanguard Global Advisers first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 400 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.